Like Mod­er­na, pan­dem­ic peers Pfiz­er and BioN­Tech head to PhI­II with Covid/flu com­bo jab

Just like Mod­er­na an­nounced a few weeks ago, Pfiz­er and BioN­Tech said they will al­so head to Phase III “in the com­ing months” for a Covid-19/flu com­bi­na­tion vac­cine, the duo dis­closed Thurs­day morn­ing.

In a near­ly 1,000-per­son Phase I/II study, their in­ves­ti­ga­tion­al mR­NA-based com­bi­na­tion vac­cine was able to drum up “ro­bust im­mune re­spons­es” to var­i­ous strains of in­fluen­za and SARS-CoV-2 com­pared to a li­censed flu shot and their Omi­cron BA.4/BA.5 bi­va­lent jab. The safe­ty was “con­sis­tent” with their Covid jab, the com­pa­nies said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER